Date: 2012-08-02
Type of information: Licensing agreement
Compound: know-how and patents (on CAP and CAP-T cell expression system) to develop stable cell lines
Company: CEVEC Pharmaceuticals (Germany) Paragon Bioservices (USA)
Therapeutic area:
Type agreement: licensing
Action mechanism:
Disease:
Details: CEVEC Pharmaceuticals, the developer of a novel, market-leading human protein expression system derived from amniocytes, and Paragon Bioservices, Inc., a contract research and GMP manufacturing organization with a focus on the development and manufacturing of biopharmaceuticals, have announced a joint collaboration whereby Paragon Bioservices would license and use CEVEC\'s know-how and patents (on CAP and CAP-T cell expression system) to develop stable cell lines and perform process development for the contract manufacturing of recombinant proteins and antibodies.
Financial terms:
Latest news:
